EDSA Quote, Financials, Valuation and Earnings

ESSA Pharma has a net margin of -- compared to Edesa Biotech's net margin of --. Edesa Biotech's return on equity of -- beat ESSA Pharma's return on equity of --.

Edesa Biotech has a consensus price target of $20.50, signalling upside risk potential of 1142.42%. On the other hand ESSA Pharma has an analysts' consensus of -- which suggests that it could grow by 492.85%. Given that Edesa Biotech has higher upside potential than ESSA Pharma, analysts believe Edesa Biotech is more attractive than ESSA Pharma.

Edesa Biotech has a beta of 0.772, which suggesting that the stock is 22.837% less volatile than S&P 500. In comparison ESSA Pharma has a beta of 1.624, suggesting its more volatile than the S&P 500 by 62.388%.

Edesa Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ESSA Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edesa Biotech pays -- of its earnings as a dividend. ESSA Pharma pays out -- of its earnings as a dividend.

Edesa Biotech quarterly revenues are --, which are smaller than ESSA Pharma quarterly revenues of --. Edesa Biotech's net income of -$962.1K is higher than ESSA Pharma's net income of -$6.4M. Notably, Edesa Biotech's price-to-earnings ratio is -- while ESSA Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edesa Biotech is 16.05x versus -- for ESSA Pharma. Usually stocks with elevated PS ratios are considered overvalued.

ImmunoPrecise Antibodies has a net margin of -- compared to Edesa Biotech's net margin of -41.68%. Edesa Biotech's return on equity of -- beat ImmunoPrecise Antibodies's return on equity of -68.99%.

Edesa Biotech has a consensus price target of $20.50, signalling upside risk potential of 1142.42%. On the other hand ImmunoPrecise Antibodies has an analysts' consensus of -- which suggests that it could grow by 1149.69%. Given that ImmunoPrecise Antibodies has higher upside potential than Edesa Biotech, analysts believe ImmunoPrecise Antibodies is more attractive than Edesa Biotech.

Edesa Biotech has a beta of 0.772, which suggesting that the stock is 22.837% less volatile than S&P 500. In comparison ImmunoPrecise Antibodies has a beta of 0.210, suggesting its less volatile than the S&P 500 by 79.036%.

Edesa Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ImmunoPrecise Antibodies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edesa Biotech pays -- of its earnings as a dividend. ImmunoPrecise Antibodies pays out -- of its earnings as a dividend.

Edesa Biotech quarterly revenues are --, which are smaller than ImmunoPrecise Antibodies quarterly revenues of $4.5M. Edesa Biotech's net income of -$962.1K is higher than ImmunoPrecise Antibodies's net income of -$1.9M. Notably, Edesa Biotech's price-to-earnings ratio is -- while ImmunoPrecise Antibodies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edesa Biotech is 16.05x versus 0.61x for ImmunoPrecise Antibodies. Usually stocks with elevated PS ratios are considered overvalued.

Lexaria Bioscience has a net margin of -- compared to Edesa Biotech's net margin of -2121.06%. Edesa Biotech's return on equity of -- beat Lexaria Bioscience's return on equity of -93.31%.

Edesa Biotech has a consensus price target of $20.50, signalling upside risk potential of 1142.42%. On the other hand Lexaria Bioscience has an analysts' consensus of -- which suggests that it could grow by 348.43%. Given that Edesa Biotech has higher upside potential than Lexaria Bioscience, analysts believe Edesa Biotech is more attractive than Lexaria Bioscience.

Edesa Biotech has a beta of 0.772, which suggesting that the stock is 22.837% less volatile than S&P 500. In comparison Lexaria Bioscience has a beta of 1.062, suggesting its more volatile than the S&P 500 by 6.234%.

Edesa Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lexaria Bioscience offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edesa Biotech pays -- of its earnings as a dividend. Lexaria Bioscience pays out -- of its earnings as a dividend.

Edesa Biotech quarterly revenues are --, which are smaller than Lexaria Bioscience quarterly revenues of $84K. Edesa Biotech's net income of -$962.1K is higher than Lexaria Bioscience's net income of -$1.8M. Notably, Edesa Biotech's price-to-earnings ratio is -- while Lexaria Bioscience's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edesa Biotech is 16.05x versus 59.30x for Lexaria Bioscience. Usually stocks with elevated PS ratios are considered overvalued.

Xenon Pharmaceuticals has a net margin of -- compared to Edesa Biotech's net margin of --. Edesa Biotech's return on equity of -- beat Xenon Pharmaceuticals's return on equity of --.

Edesa Biotech has a consensus price target of $20.50, signalling upside risk potential of 1142.42%. On the other hand Xenon Pharmaceuticals has an analysts' consensus of $57.67 which suggests that it could grow by 49.05%. Given that Edesa Biotech has higher upside potential than Xenon Pharmaceuticals, analysts believe Edesa Biotech is more attractive than Xenon Pharmaceuticals.

Edesa Biotech has a beta of 0.772, which suggesting that the stock is 22.837% less volatile than S&P 500. In comparison Xenon Pharmaceuticals has a beta of 1.189, suggesting its more volatile than the S&P 500 by 18.926%.

Edesa Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xenon Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edesa Biotech pays -- of its earnings as a dividend. Xenon Pharmaceuticals pays out -- of its earnings as a dividend.

Edesa Biotech quarterly revenues are --, which are smaller than Xenon Pharmaceuticals quarterly revenues of --. Edesa Biotech's net income of -$962.1K is higher than Xenon Pharmaceuticals's net income of -$62.8M. Notably, Edesa Biotech's price-to-earnings ratio is -- while Xenon Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edesa Biotech is 16.05x versus 222.63x for Xenon Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.